Effects of protein restriction, melatonin administration, and short daylength on brain benzodiazepine receptors in prepubertal male rats

Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines

Kynuramines represent their own class of biogenic amines. They are formed either by decarboxylation of kynurenines or pyrrole ring cleavage of indoleamines. N(2)-formylated compounds formed in this last reaction can be deformylated either enzymatically by arylamine formamidases or hemoperoxidases, or photochemically. The earlier literature mainly focussed on cardiovascular effects of kynuramine, 5-hydroxykynuramine and their N(1),N(1)-dimethylated analogs, including indirect effects via release of catecholamines or acetylcholine and interference with serotonin receptors. After the discovery of N(1)-acetyl-N(2)-formyl-5-methoxykynuramine (AFMK) and N(1)-acetyl-5-methoxykynuramine (AMK) as major brain metabolites of melatonin, these compounds became of particular interest. They were shown to be produced enzymatically, pseudoenzymatically, by various free radical-mediated and via photochemical processes. In recent years, AFMK and AMK were shown to scavenge reactive oxygen and nitrogen species, thereby forming several newly discovered 3-indolinone, cinnolinone and quinazoline compounds, and to protect tissues from damage by reactive intermediates in various models. AMK is of special interest due to its properties as a potent cyclooxygenase inhibitor, NO scavenger forming a stable nitrosation product, inhibitor and/or downregulator of neuronal and inducible NO synthases, and a mitochondrial metabolism modulator. AMK easily interacts with aromates, forms adducts with tyrosyl and tryptophanyl residues, and may modify proteins.

Effect of melatonin on the regulation of proenkephalin and prodynorphin mRNA levels induced by kainic acid in the rat hippocampus

The in vivo short-term effect of melatonin on kainic acid (KA)-induced proenkephalin (proENK) or prodynorphin (proDYN) mRNA, and on AP-1 protein levels in the rat hippocampus, were studied. Melatonin (5 mg/kg) or saline was administered intraperitoneally (i.p.) to rats 30 min prior to and immediately after i.p. injection of KA (10 mg/kg). Rats were sacrificed 1 and 3 h after KA injection. The proENK and proDYN mRNA levels were significantly increased 3 h after KA administration. The elevations of both proENK and proDYN mRNA levels induced by KA were significantly inhibited by the preadministration with melatonin. The increases of proENK and proDYN mRNA levels induced by KA were well-correlated with the increases of c-Fos, Fra-2, FosB, c-Jun, and JunB protein levels, which were significantly increased 3 h after KA administration and effectively inhibited by administration with melatonin. In an electrophoretic mobility shift assay, both AP-1 and ENKCRE-2 DNA binding activities were increased by KA, which were also attenuated by the administration of melatonin. In addition, cross-competition studies revealed that AP-1 or ENKCRE-2 DNA binding activity was effectively reduced by the 50x unlabeled cross-competitor. Therefore, these data suggest that melatonin has an inhibitory role in KA-induced gene expression, such as proENK and proDYN mRNA expression, and this may be due to a reduction of KA-induced AP-1 or ENKCRE-2 DNA binding activity.

Melatonin reduces oxidative neurotoxicity due to quinolinic acid: in vitro and in vivo findings

The in vivo and in vitro effects of melatonin on quinolinic acid-induced oxidative damage in rat brain were determined. The concentrations of malonaldehyde and 4-hydroxyalkenals were assayed as an index of oxidatively damaged lipid. In in vitro experiments, the increase in malonaldehyde and 4-hydroxyalkenals concentrations induced by quinolinic acid were concentration-dependent and time-dependent. The accumulation of products of lipid peroxidation induced by quinolinic acid were very significantly reduced by melatonin in a concentration-dependent manner. Additionally, at the highest concentrations of melatonin used in quinolinic acid treated homogenates, it reduced the levels of oxidatively damaged lipid products below those measured in control homogenates (no quinolinic acid or melatonin). When quinolinic acid (200 mg/kg) was intraperitonally injected into 11-day-old rats, lipid peroxidation in the brain was significantly increased 24 hours later compared to levels in control rats. When melatonin (10 mg/kg) was injected i.p. 30 min before and 4 and 20 hours after the administration of quinolinic acid, the increased lipid peroxidation induced by quinolinic acid was significantly reduced. Likewise, neurobehavioral signs associated with quinolinate administration were attenuated by melatonin. These results show that both in vitro and in vivo pharmacological levels of melatonin confer protection against quinolinic acid-induced oxidative toxicity in the brain. The findings also indicate that melatonin may be pharmacologically useful in combatting quinolinic neurotoxicity which is associated with several acute and chronic neurodegenerative neurological diseases.

Melatonin effects on behavior: possible mediation by the central GABAergic system

The best described function of the pineal hormone melatonin is to regulate seasonal reproduction, with its daily production and secretion varying throughout the seasons or the photoperiod. Additionally, a number of behavioral effects of the hormone have been found. This review describes the effects of melatonin in rodent behavior. We focus on: (a) inhibitory effects (sedation, hypnotic activity, pain perception threshold elevation, anti-convulsive activity, anti-anxiety effects); and (b) direct effects on circadian rhythmicity (entrainment, resynchronization, alleviation of jet-lag symptoms, phase-shifting). Most of these effects are clearly time-dependent, with a peak of melatonin activity during the night. One of the possible mechanisms of action for melatonin in the brain is the interaction with the GABAergic system, as suggested by neurochemical and behavioral data. Finally, some pineal hormone effects might be candidates as putative therapies for several human disorders.

Melatonin replacement nullifies the effect of light-induced functional pinealectomy on nociceptive rhythm in the rat

Rats maintained on a 12 h daily photoperiod (12:12 LD cycle), exhibited a diurnal variation in sensitivity to both heat-elicited and pressure-elicited pain, with low sensitivity at 2 h before the end of the scotophase and higher at 4 h after the onset of photophase. Functional pinealectomy induced by a single LL day effaced the baseline diurnal rhythm of sensitivity to pressure-elicited pain, and reversed that to heat-elicited pain. Oral administration of physiological doses of melatonin into functionally pinealectomized rats, nullified the effect of functional pinealectomy, restoring the normal baseline rhythms of both pressure-elicited and heat-elicited nociceptive responses. The role of melatonin in modulating nociception is discussed in light of an indoleaminergic-opioid system.

Effect of a phase advance of the light/dark cycle on pineal function and circadian running activity in individual rats

Circadian rhythms of urinary 6-sulphatoxy-melatonin excretion and spontaneous wheel-running activity were monitored in individual male Wistar albino and hooded rats entrained to a 12 h L:12 h D photoperiod, before and after an 8 h phase advance of the light cycle. The pigmented hooded strain commenced melatonin metabolite excretion 2 h after darkness, whereas the albino rats did not excrete detectable amounts until 4 h of darkness had elapsed (p < 0.05). There was no correlation between the time of onset of spontaneous wheel-running activity and the onset of excretion of 6-sulphatoxymelatonin under entrained conditions. When the photoperiod was advanced by 8 h, the albino rats took a median of 4 days (range 2-10 days) to establish a normal phase angle for the onset of 6-sulphatoxymelatonin excretion in contrast to the pigmented rats, which took in excess of 10 days to entrain. Albino rats reentrained running activity significantly earlier than pigmented rats (8 days: range 6-9 days), compared to 10 days (range 8 to > 12 days). There was no consistent relationship between the pineal and running rhythms with respect to the time taken to entrain following a lighting phase shift. All rats entrained the 6-sulphatoxymelatonin rhythm by advancing the onset of excretion in contrast to the running rhythm where three rats reentrained by advancing, three by delaying, and in four, the direction of entrainment could not be accurately determined. In two of the animals (both albino), there was unequivocal evidence that the 6-sulphatoxymelatonin rhythm and running reentrained in different directions.(ABSTRACT TRUNCATED AT 250 WORDS)

The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances

Recent findings suggest that the ability of melatonin to enter all body tissues and to be metabolized, enzymatically or nonenzymatically, in any of them results in a spectrum of effects, which exceed substantially those transduced by membrane receptors. These actions comprise the formation of various bioactive compounds such as N-acetylserotonin, 5-methoxytryptamine, N,N-dimethyl-5-methoxytryptamine, 5-methoxytryptophol, cyclic 2-hydroxymelatonin, pinoline, and 5-methoxylated kynuramines. Apart from enzymatic metabolism, nonenzymatic reactions with free radicals, in particular the superoxide anion and the hydroxyl radical, represent a new and significant aspect of melatonin's biological role. Melatonin represents the most potent physiological scavenger of hydroxyl radicals found to date, and recent findings suggest an essential role of this indoleamine for protection from hydroxyl radical-induced carcinogenesis and neurodegeneration.

Diurnal changes of GABA turnover rate in brain and pineal gland of Syrian hamsters

Circadian rhythms of GABA turnover rate in cerebral cortex, preoptic area-medial basal hypothalamus (PMBH), cerebellum, and pineal gland were examined in Syrian hamsters kept for 3 months under either long (14 h of light/day) or short days (10 h of light/day). In vivo GABA turnover rate was measured by the increase of GABA levels following inhibition of GABA-transaminase by gamma-acetylenic GABA. Under long photoperiods, a significant rhythm of GABA turnover was detected in the four areas studied (cerebral cortex, PMBH, cerebellum, and pineal gland), with maxima at night. A Cosinor analysis indicated acrophases which varied from 2300 to 0400 h (3rd to 8th h of darkness). Under short photoperiods, there were no significant circadian variations in GABA turnover in the cerebral cortex, and the synchronization in turnover rate among the remaining regions was lost, with acrophases being detectable either during the light phase of daily photoperiod (PMBH) or at night (cerebellum, pineal gland). Steady state levels of GABA also changed periodically in the same brain regions under both lighting environments, although phase relationships of circadian rhythms in GABA content and turnover rate varied significantly among tissues, as well as on photoperiodic conditions.

Chronopharmacology of melatonin: inhibition by benzodiazepine antagonism

We endeavored to determine whether three behavioral effects of melatonin in rodents, i.e., depression of locomotor activity in hamsters, analgesia in mice, and impairment of 3-mercaptopropionic acid (3-MP) convulsions, exhibited the time dependency known to occur for several neuroendocrine effects of the hormone. Activity was monitored and registered by means of an optical actometer, and analgesia was assessed by the hot-plate procedure. Locomotor activity, analgesia, and seizure susceptibility were maximal at the beginning of the scotophase and minimal at noon. The effects of melatonin on the three parameters peaked at early night. The administration of the benzodiazepine antagonist flumazenil, although unable by itself to modify locomotor activity, pain, or seizure threshold, blunted the activity of melatonin. These results suggest that the time-dependent effects of melatonin on specific rodent behaviors may be mediated by central synapses employing gamma-aminobutyric acid (GABA) as an inhibitory transmitter.

Time-dependent anticonvulsant activity of melatonin in hamsters

The objective of the present study was to assess whether the anticonvulsant activity of melatonin displays diurnal variability in hamsters. Convulsions were induced by administering 3-mercaptopropionic acid (3-MP). There was a significant diurnal variation in 3-MP-induced convulsions, hamsters being more prone to exhibit seizures during the night than during the day. Melatonin (50 mg/kg i.p.) had a maximal anticonvulsive effect in the early evening (20:00 h). The administration at 20:00 h of the central-type benzodiazepine antagonist, Ro 15-1788, although unable by itself to modify seizure threshold, blunted the anticonvulsant response to melatonin. The results indicate that the time-dependent anticonvulsant activity of melatonin is sensitive to central-type benzodiazepine antagonism.

Melatonin-induced depression of locomotor activity in hamsters: time-dependency and inhibition by the central-type benzodiazepine antagonist Ro 15-1788

The aim of the present study was to determine whether melatonin-induced depression of locomotor activity in hamsters is time-dependent and to analyze the inhibitory effects of the central-type benzodiazepine (BZP) antagonist Ro 15-1788 on melatonin-induced depression of locomotor behavior. Activity was monitored and registered by means of an optical actometer. Two phases of locomotor behavior were found. The initial phase, found both at noon and during the evening, exhibited an absence of diurnal variability, while a second long-lasting phase of activity exhibited a peak at early night. The IP injection of melatonin (minimal effective dose: 100 micrograms/kg) inhibited the early phase of activity at 1200 or 2000 h. Inhibition of the late phase of activity was found at 2000 or 0400 h, but not at midnight. When assessed at 2000 h, melatonin depression of the early phase of locomotor activity attained significance after 5 days of injection, while its effect on the late phase of activity attained significance during the second day of injection. The administration of Ro 15-1788, although unable by itself to modify locomotor activity, significantly attenuated the inhibitory effects of melatonin. These results indicate the existence of a time-dependency for melatonin activity on locomotor behavior similar to that known to occur for other effects of the hormone, and further support a link between melatonin and the activity of central type BZP receptors.

Time-dependent melatonin analgesia in mice: inhibition by opiate or benzodiazepine antagonism

The aim of this study was to determine whether melatonin-induced analgesia in mice exhibits the time dependency known to occur for several other effects of the hormone, and to analyze to what extent the activity of melatonin can be inhibited by the opiate antagonist naloxone or the central-type benzodiazepine (BZP) antagonist Ro 15-1788. Analgesia was assessed with the hot plate procedure. There was a significant diurnal variation in the pain threshold, with an increase in latency during the dark phase of the daily photo period. Melatonin (20-40 mg/kg i.p.) exhibited maximal analgesic effects at late evening (20:00 h). The administration of naloxone or Ro 15-1788 at 20:00 h, although unable by themselves to modify pain threshold, blunted the analgesic response to melatonin. Significant increases in the latency of the hot plate response were found after diazepam injection, an effect blocked by Ro 15-1788 or naloxone. These results indicate that time-dependent melatonin analgesia is sensitive to opioid or central-type BZP antagonism.

Time-Dependent Effect of Melatonin on Glutamic Acid Decarboxylase Activity and CI Influx in Rat Hypothalamus

Abstract The objective of the first series of experiments was to assess whether melatonin treatment modifies the activity of the y-aminobutyric acid synthesizing enzyme, glutamic acid decarboxylase, in the preoptic-medial basal hypotnalamic area, cerebral cortex and cerebellar cortex of rats receiving 25 to 300 mug of melatonin in the early morning and late evening in the diurnal cycle. A significant increase of apparent V(max) and K(m) of the enzyme was found in the hypothalamus of rats killed at the 12th h of the light phase (i.e. the time when lights were turned off) and receiving 25 to 300 mug/kg of melatonin 3 h earlier. In the early morning, only a 300 mug/kg dose of melatonin (injected in the 1st h of the light phase) was effective to increase V(max) and K(m) of hypothalamic glutamic acid decarboxylase 3 h later. In cerebral and cerebellar cortices, increases in V(max) and K(m) of enzyme activity were apparent only in the evening and with the highest melatonin dose employed (300 mug/kg). In a second series of experiments the activity of melatonin to modify in vitro(36)CI influx by 900 x g pellets of rat preoptic-medial basal hypothalamic area was studied at the 4th and 12th h of the light phase of daily photoperiod. Melatonin increased (36)CI(-) influx at a minimum concentration of 100 nM (in the morning) or 10 nM (in the evening). The effect of melatonin on (36)CI(-) influx was prevented by co-incubation with 100 muM picrotoxin. Addition of 10 to 100 muM of y-aminobutyric acid to the resuspended 900 x g pellets brought about a dose-dependent increase of (36)CI (-) influx. Preincubation with melatonin at threshold doses of 1 muM (in the morning) or 0.1 muM (in the evening) significantly augmented y-aminobutyric acid effect on (36)CI(-) uptake. These results indicate that melatonin facilitates pre- and postsynaptic activities of y-aminobutyric acid neurons, particularly in the hypothalamus, through an effect that displays a diurnal sensitivity compatible with the documented activity of the hormone on a number of physiological functions.